Virus World
377.6K views | +38 today
Follow
Virus World
Virus World provides a daily blog of the latest news in the Virology field and the COVID-19 pandemic. News on new antiviral drugs, vaccines, diagnostic tests, viral outbreaks, novel viruses and milestone discoveries are curated by expert virologists. Highlighted news include trending and most cited scientific articles in these fields with links to the original publications. Stay up-to-date with the most exciting discoveries in the virus world and the last therapies for COVID-19 without spending hours browsing news and scientific publications. Additional comments by experts on the topics are available in Linkedin (https://www.linkedin.com/in/juanlama/detail/recent-activity/)
Curated by Juan Lama
Your new post is loading...
Scooped by Juan Lama
Scoop.it!

Covid Vaccines Cut Risk of Virus-Related Heart Failure and Blood Clots, Study Finds - The Guardian

Covid Vaccines Cut Risk of Virus-Related Heart Failure and Blood Clots, Study Finds - The Guardian | Virus World | Scoop.it

Covid vaccinations substantially reduce the risk of heart failure and potentially dangerous blood clots linked to the infection for up to a year, according to a large study. Researchers analysed health records from more than 20 million people across the UK, Spain and Estonia and found consistent evidence that the jabs protected against serious cardiovascular complications of the disease. Covid vaccines, including those from Oxford-AstraZeneca, Pfizer and Moderna, proved highly effective at preventing severe disease in the pandemic, but medicines regulators also recorded increases in some rare heart and clotting conditions, similar to those found with other vaccines such as flu shots.

 

The latest study sought to investigate the overall impact of a Covid vaccination, given that infection with the virus itself is known to significantly raise the risk of heart failure and various other serious cardiovascular problems. “What we show in this very large study is that people who are vaccinated are at a very much reduced risk of these complications post-Covid,” said Daniel Prieto-Alhambra, a professor of pharmaco- and device epidemiology at the University of Oxford and a senior author on the study. Writing in the journal Heart, the researchers describe how the adenovirus-based Covid vaccines produced by Oxford-AstraZeneca and Janssen, and the mRNA-based vaccines from Pfizer and Moderna, were most protective against Covid-related heart failure and blood clots in the first month after contracting the virus. In that period, the risk of heart failure was 55% lower, and the risks of blood clots in the veins and arteries were down 78% and 47% respectively, compared with rates in unvaccinated people.

 

While the protective effects of the vaccines waned over the longer term, those who received Covid shots remained at lower risk of Covid-related heart failure and blood clots than unvaccinated individuals for up to a year, the researchers found. Three to six months after infection, the risk of heart failure in vaccinated people was 39% lower than in unvaccinated people, with the risk of blood clots in the veins and arteries down 47% and 28% respectively. From six to 12 months post-infection, the risks of the same complications were 48%, 50% and 38% lower, respectively, for vaccinated people. The protective effect arises from the vaccines reducing the severity of the disease when people experience breakthrough infections, when the virus takes hold despite a person being vaccinated. “The message overall is that if you are vaccinated, your risk of having post-Covid cardiovascular and thromboembolic complications is reduced quite dramatically,” Prieto-Alhambra said. “Particularly for people who are at high risk, or are scared of having cardiovascular complications or blood clots, this is very reassuring.”

 

 

Cites study published in 2024 in BMJ Heart:

https://doi.org/10.1136/heartjnl-2023-323483 

 
No comment yet.
Scooped by Juan Lama
Scoop.it!

Risk Factors Predisposing to Death by COVID-19

Risk Factors Predisposing to Death by COVID-19 | Virus World | Scoop.it

Coronavirus disease 2019 (Covid-19) may disproportionately affect people with cardiovascular disease. Concern has been aroused regarding a potential harmful effect of angiotensin-converting–enzyme (ACE) inhibitors and angiotensin-recep- tor blockers (ARBs) in this clinical context.

 

Using an observational database from 169 hospitals in Asia, Europe, and North America, we evaluated the relationship of cardiovascular disease and drug therapy with in-hospital death among hospitalized patients with Covid-19 who were admit- ted between December 20, 2019, and March 15, 2020, and were recorded in the Surgical Outcomes Collaborative registry as having either died in the hospital or survived to discharge as of March 28, 2020. 

 

Of the 8910 patients with Covid-19 for whom discharge status was available at the time of the analysis, a total of 515 died in the hospital (5.8%) and 8395 survived to discharge. The factors we found to be independently associated with an in- creased risk of in-hospital death were an age greater than 65 years (mortality of 10.0%, vs. 4.9% among those ≤65 years of age; odds ratio, 1.93; 95% confidence interval [CI], 1.60 to 2.41), coronary artery disease (10.2%, vs. 5.2% among those without disease; odds ratio, 2.70; 95% CI, 2.08 to 3.51), heart failure (15.3%, vs. 5.6% among those without heart failure; odds ratio, 2.48; 95% CI, 1.62 to 3.79), cardiac arrhythmia (11.5%, vs. 5.6% among those without arrhythmia; odds ratio, 1.95; 95% CI, 1.33 to 2.86), chronic obstructive pulmonary disease (14.2%, vs. 5.6% among those without disease; odds ratio, 2.96; 95% CI, 2.00 to 4.40), and current smoking (9.4%, vs. 5.6% among former smokers or nonsmokers; odds ratio, 1.79; 95% CI, 1.29 to 2.47). No increased risk of in-hospital death was found to be associated with the use of ACE inhibitors (2.1% vs. 6.1%; odds ratio, 0.33; 95% CI, 0.20 to 0.54) or the use of ARBs (6.8% vs. 5.7%; odds ratio, 1.23; 95% CI, 0.87 to 1.74).

 

Our study confirmed previous observations suggesting that underlying cardiovascu- lar disease is associated with an increased risk of in-hospital death among patients hospitalized with Covid-19. Our results did not confirm previous concerns regarding a potential harmful association of ACE inhibitors or ARBs with in-hospital death in this clinical context....

 

In our analyses, use of either ACE inhibitors or statins was associated with better survival among patients with Covid-19. However, these as- sociations should be considered with extreme cau- tion. Because our study was not a randomized, controlled trial, we cannot exclude the possibility of confounding.

 

Published in New England. J. Medicine (May 1, 2020):

https://doi.org/10.1056/NEJMoa2007621

 

No comment yet.